C4 Therapeutics, Inc.
Every calculator, already run for CCCC
Open the full toolkit →You have the numbers on CCCC. Get the argument.
A written report on which of these readings actually decide the outcome for C4 Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering CCCCAnalyst Price Target Disagreement for C4 Therapeutics, Inc.
Wall Street's bull case implies +912% from the current price; the bear case implies +136%. A 776% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CCCC
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaboration…
CCCC — frequently asked
Is CCCC a buy right now?
Wall Street's consensus rating on C4 Therapeutics, Inc. is none across 7 analysts, with a mean price target of $13.33 (+350% vs. the current $2.97). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CCCC's next earnings date?
C4 Therapeutics, Inc. is next scheduled to report earnings around Nov 5, 2026. A full CCCC research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for C4 Therapeutics, Inc.?
Analysts covering C4 Therapeutics, Inc. (CCCC) range from a bear-case target of $7.00 to a bull-case high of $30.00, with a mean consensus target of $13.33 across 6 analysts. The spread of $23.00 (776% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare C4 Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For C4 Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CCCC research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on C4 Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.